Luchkanych Adam M S, Barlage Breanna, Delgado Gabriela, Morton Jude S, Morse Cameron J, Boerman Erika M, Hoiland Ryan L, Sekhon Mypinder S, Tymko Michael M, Padilla Jaume, Emter Craig A, Tomczak Corey R, Laughlin M Harold, Olver T Dylan
Department of Biomedical Sciences, Western College of Veterinary Medicine University of Saskatchewan Saskatoon SK Canada.
Department of Medical Physiology and Pharmacology University of Missouri Columbia MO USA.
J Am Heart Assoc. 2025 Oct 7;14(19):e042396. doi: 10.1161/JAHA.125.042396. Epub 2025 Sep 25.
Phenylephrine is an alpha 1-adrenergic receptor (α1R) agonist. Evidence indicates activation of α1Rs can initiate both vasoconstrictor and dilator signaling. How phenylephrine affects cerebrovascular regulation remains unclear.
A retrospective analysis of data examining cerebral perfusion and blood pressure during systemic phenylephrine infusion in humans and swine was completed. Follow-up experiments examining cerebral hemodynamics during intracarotid arterial infusion of phenylephrine in anesthetized swine were performed. Ex vivo experiments were conducted on isolated porcine cerebral arteries.
Systemic phenylephrine infusion increased indices of cerebrovascular resistance in both humans (=0.0423) and swine (<0.0001) but did not decrease perfusion. Intracarotid phenylephrine infusion did not alter cerebrovascular resistance, but increased perfusion in control conditions (=0.0045), whereas resistance increased (≤0.0155) without altered perfusion during NOS (nitric oxide synthase) inhibition conditions. α1Rs were detected on both extraluminal and intraluminal aspects of cerebral arteries, reflecting a population of vascular smooth muscle and endothelial α1Rs, respectively. Extraluminal phenylephrine caused vasoconstriction whereas intraluminal phenylephrine elicited an endothelium-dependent NO-mediated dilation. NOS inhibition enhanced phenylephrine-induced vasoconstriction in third-order branch of the middle cerebral artery, but not the first-order or second-order pial arteries (=0.0267), and this corresponded with an increased ratio of phosphorylated to total endothelial NOS protein content in third-order versus first-order and second-order arteries (≤0.0022). Phenylephrine-induced constriction was greatest in first-order arteries (=0.0419), and this corresponded with increased perivascular adrenergic innervation and α1R protein content in first-order versus second-order and third-order arteries (≤0.0054).
Neither systemic nor intracarotid phenylephrine infusion compromised cerebral perfusion, possibly related to increased endothelial NO signaling and reduced α1R density in downstream pial arteries.
去氧肾上腺素是一种α1-肾上腺素能受体(α1R)激动剂。有证据表明,α1R的激活可启动血管收缩和舒张信号传导。去氧肾上腺素如何影响脑血管调节仍不清楚。
完成了一项回顾性分析,该分析检测了人类和猪在全身输注去氧肾上腺素期间的脑灌注和血压。进行了后续实验,检测麻醉猪在颈内动脉输注去氧肾上腺素期间的脑血流动力学。对分离的猪脑动脉进行了体外实验。
全身输注去氧肾上腺素增加了人类(P = 0.0423)和猪(P < 0.0001)的脑血管阻力指数,但未降低灌注。颈内输注去氧肾上腺素未改变脑血管阻力,但在对照条件下增加了灌注(P = 0.0045),而在一氧化氮合酶(NOS)抑制条件下,阻力增加(P≤0.0155),灌注未改变。在脑动脉的管腔外和管腔内均检测到α1R,分别反映了血管平滑肌和内皮α1R的群体。管腔外去氧肾上腺素引起血管收缩,而管腔内去氧肾上腺素引起内皮依赖性一氧化氮介导的舒张。NOS抑制增强了去氧肾上腺素诱导的大脑中动脉三级分支的血管收缩,但未增强一级或二级软脑膜动脉的血管收缩(P = 0.0267),这与三级动脉与一级和二级动脉中磷酸化内皮型NOS蛋白与总内皮型NOS蛋白含量的比值增加相对应(P≤0.0022)。去氧肾上腺素诱导的收缩在一级动脉中最大(P = 0.0419),这与一级动脉与二级和三级动脉中血管周围肾上腺素能神经支配和α1R蛋白含量增加相对应(P≤0.0054)。
全身或颈内输注去氧肾上腺素均未损害脑灌注,这可能与内皮一氧化氮信号增加和下游软脑膜动脉中α1R密度降低有关。